LINK Medical is pleased to announce the end of recruitment in Lipigon Pharmaceuticals’ Phase II clinical study of Lipisense®, finalized on June 23, 2025. The study is designed to assess the safety and tolerability of Lipisense® in Swedish patients with moderately to severely elevated blood lipid levels. In total, 23 patients were enrolled. The final treatment visits are expected to be completed in the coming weeks, with preliminary results anticipated by the end of 2025.
As the selected contract research organization (CRO), LINK Medical has delivered comprehensive clinical support throughout the study, including project management, site monitoring, regulatory guidance, and data handling.
“The strong collaboration between the sponsor, study sites, and our team enabled the enrollment of 23 patients and was key to reaching this important milestone,” said Sabina Lundblad, Clinical Project Manager at LINK Medical.
Lipisense® is an RNA-based drug candidate targeting angiopoietin-like protein 4 (ANGPTL4), a protein associated with elevated triglycerides and related conditions such as acute pancreatitis and cardiovascular disease. In addition to evaluating safety and tolerability, the study also explores the potential therapeutic impact on lipid biomarkers including triglycerides, remnant cholesterol, and insulin sensitivity.
LINK Medical is a Nordic full-service CRO providing flexible and high-quality support to biotech, medtech and pharmaceutical companies across all phases of clinical development.
For further information, please contact:
LINK Medical Communications
Email: info@linkmedical.eu
www.linkmedical.eu
Read Lipigon’s full press release:
Lipigon Pharmaceuticals Enrolls Last Patient in Phase II Study with Lipisense®